No registrations found.
ID
Source
Brief title
Health condition
Eosinophilic esophagitis, treatment, elemental diet, amino acid based formula, eosinophils, gastrointestinal barrier function
Sponsors and support
Intervention
Outcome measures
Primary outcome
Change in esophageal mucosalpeak eosinophil count, measured as maximum number of eosinophils per hpf. Response is defined as complete when the peak eosinophil count decreases to <15 eos/hpf.
Secondary outcome
Measures of mucosal barrier function:
- Esophageal and duodenal permeability measured in vivo (electrical tissue impedance spectroscopy) and ex vivo (Ussing chambers experiments)
- Intestinal permeability testing using a PEG absorption
– Urine excretion test
Clinical parameters:
- Questionnaires
- Symptoms (dysphagia, food impaction) (Baseline and after 4 week)
- Patient acceptation of and adherence to the diet (every week)
- Quality of life (SF-36) Baseline and after 4 weeks
- Endoscopic features
- Correlation between primary/secondary parameters and intestinal permeability
- Adherence to the diet
- Empty drink packages will be stored by the patient and they will be asked to note the date of consumption on it
- A questionnaire “Studie productinname” will be filled in weekly
Laboratory investigations:
- Immunohistochemical analyses of esophageal and duodenal biopsy material to assess expression and localization of proteins involved in barrier function
- Serum biomarkers (total IgE, eosinophil count, IL-5, IL-13, eotaxin-3, eosinophil-derived neurotoxin)
- Transcriptional analyses: microarray or focused qPCR. Genes to be analyzed by qPCR involve:
- Activity markers of EoE (IL-5, IL-13, eotaxin-3, TGF-B)
- Tight junction proteins (Claudins, ZO-3, occludin, filaggrin, desmoglein)
- Inflammatory genes (IL-6, IL-10, TNFá, CCL-2, CCL-5, CCL-20, LAG3, ICAM1, caspases 1-14)
- If other assessments show differences between the groups optionally the gastrointestinal microbiome will be analyzed.
Background summary
Eosinophilic esophagitis (EoE) is an increasingly encountered disease for which yet no acceptable medical treatment exists. There is sufficient evidence to state that food allergy plays an important role in EoE and dietary treatment has proven efficacy in these patients. It has been suggested that elemental nutrition is an effective treatment for these patients. In this trial we will study the effect of Neocate elemental nutrition on the esophageal eosinophilic inflammation in adult patients with eosinophilic esophagitis. Furthermroe we will study the effect of Neocate elemental nutrition on esophageal and intestinal mucosal integrity, esophageal inflammation, endoscopic signs, symptoms and quality of life, and the gastrointestinal microbiome in these patients.The EoE patients will consume an elemental diet for 4 weeks. Baseline upper endoscopy with tissue impedance measurements is performed and esophageal & duodenal biopsies are taken in EoE patients and healthy volunteers. Symptoms, quality of life, and product acceptability are being investigated using questionnaires. Furthermore, the intestinal barrier function will be measured using a dual sugar method by calculating lactulose:mannitol (L:M) ratio and saliva and feces are collected to optionally assess the indigenous microbiota. In EoE patients, these measurements are repeated after 4 weeks of elemental nutrition.
Study objective
To study the effect of Neocate elemental nutrition on the esophageal eosinophilic inflammation in adult patients with eosinophilic esophagitis. Secondary: to study the effect of Neocate elemental nutrition on esophageal and intestinal mucosal integrity, esophageal inflammation, endoscopic signs, symptoms and quality of life, and the gastrointestinal microbiome in these patients.
Study design
The EoE patients will consume an elemental diet for 4 weeks. Baseline upper endoscopy with tissue impedance measurements is performed and esophageal & duodenal biopsies are taken in EoE patients and healthy volunteers. Symptoms, quality of life, and product acceptability are being investigated using questionnaires. Furthermore, the intestinal barrier function will be measured using a dual sugar method by calculating lactulose:mannitol (L:M) ratio and saliva and feces are collected to optionally assess the indigenous microbiota. In EoE patients, these measurements are repeated after 4 weeks of elemental nutrition.
Intervention
Elemental diet preceded by and followed by gastroscopy, vena puncture, salive, feces and urine analysis.
M. Warners
Department of Gastroenterology and Hepatology Academic Medical Center, room
C2-321 Meibergdreef 9
Amsterdam 1105 AZ
The Netherlands
+ 31 (0)20 5665584
m.j.warners@amc.uva.nl
M. Warners
Department of Gastroenterology and Hepatology Academic Medical Center, room
C2-321 Meibergdreef 9
Amsterdam 1105 AZ
The Netherlands
+ 31 (0)20 5665584
m.j.warners@amc.uva.nl
Inclusion criteria
- Previous diagnosis of EoE confirmed by histopathology e.g. presence of >15 eosinophilic granulocytes per high power field (hpf) in mid or proximal esophageal biopsies before the start of any therapy
- Currently experiencing dysphagia
- Written informed consent
- Age 18 – 75 years
Healthy controls:
- Written informed consent
- Age 18 – 75 years
Exclusion criteria
Patients:
- Inability to stop topical corticosteroids
- Use of systemic corticosteroids, leukotriene inhibitors, or monoclonal antibodies, in the month preceding the study
- Use of anticoagulants at study entry
- Use of NSAIDs without possibility to stop
- History of peptic ulcer disease
- History of Barrett’s esophagus
- History of GI cancer
- History of GI tract surgery (except appendectomy)
- ASA class IV or V
Healthy controls:
- Use of systemic corticosteroids, leukotriene inhibitors, or monoclonal antibodies in the month preceding the study
- Use of anticoagulants at study entry
- Use of NSAIDs without possibility to stop
- Personal history of atopic, skin or systemic diseases
- Symptoms suggestive of esophageal disease
- History of GI cancer
- History of GI tract surgery (except appendectomy)
- History of PPI, H2-receptor antagonist, or prokinetic drug use
- ASA class IV or V
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4687 |
| NTR-old | NTR4892 |
| Other | : Dossiernummer NL49502.018.14, ABR Nummer49502 |